Lapatinib Terminated Phase 1 Trials for HER-2 Positive Breast Cancer / Malignant Neoplasm of Breast Treatment

IndicationsStatusPurposePhase
TerminatedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT02131506A Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast Cancer